Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, net sales totaled $5 million, a 12% sequential increase from the fourth quarter of fiscal 2025, but a slight decrease from $5.1 million in the prior year period [12] - Gross margin decreased to 60% from 66% in the prior year, primarily due to increased warehouse expenses and a shift in revenue mix towards wholesale [12] - Net loss attributable to common shareholders improved to approximately $325,000, or $0.04 per share, compared to a net loss of approximately $1 million, or $1.73 per share in the prior year quarter [13] Business Line Data and Key Metrics Changes - Direct-to-consumer sales represented approximately 72% of total revenue, while wholesale business accounted for 28% of revenue, showing a year-over-year growth of 17% [5] - The wholesale growth reflects improved execution in the core cbdMD brand and ongoing progress with the beverage brand, Oasis [5] Market Data and Key Metrics Changes - The company reported three consecutive quarters of sequential revenue growth, indicating positive trends in the business despite a challenging regulatory environment [4] - December 2025 and January 2026 marked the highest monthly revenue levels since 2022, suggesting a recovery in core business performance [4] Company Strategy and Development Direction - The company is focused on reducing fixed costs, simplifying operations, and strengthening the balance sheet to position for regulated growth [5] - The acquisition of Bluebird Botanicals is seen as strategically important, adding incremental revenue and a loyal customer base, while also enhancing regulatory and scientific positioning [7][8] - The company aims to maintain separate brand identities for Bluebird and cbdMD to cater to different customer bases [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term runway supported by a strong cash position and the incremental benefits from the Bluebird acquisition [15] - The regulatory environment remains uncertain, but recent bipartisan efforts to revisit restrictive hemp legislation are viewed positively [10] - The company is focused on generating positive EBITDA and managing cash carefully to support sustainable operating results [14] Other Important Information - The company completed approximately $2.25 million in Series C Preferred financing, strengthening liquidity and working capital [9] - As of December 31, 2025, cash and cash equivalents increased to approximately $3.4 million, reflecting improved liquidity [14] Q&A Session Summary Question: Insights on the integration of Bluebird Botanicals - Management indicated that they have brought over some team members from Bluebird and see opportunities for growth by leveraging their expertise and improving marketing activities [19] Question: Plans for integrating e-commerce capabilities - The company intends to maintain Bluebird as a separate brand due to differences in customer bases, allowing for continued growth [22] Question: Contribution of the Oasis line of seltzers to sales - While Oasis is starting to contribute, it remains small relative to the overall size of the core cbdMD brand, with expectations for improvement throughout the year [24]

cbdMD (NYSEAM:YCBD) Q1 2026 Earnings call February 17, 2026 04:20 PM ET Speaker1Good afternoon. Welcome, ladies and gentlemen, to cbdMD, Inc.'s December 31st, 2025, first fiscal quarter of 2026 earnings call and update. This afternoon, the company issued a press release that provided an overview of its first quarter results, which followed the filing of its quarterly report on, excuse me, on Form 10-Q. Today's conference call is being recorded and will be available online, along with our earnings press rele ...

ReposiTrak (NYSE:TRAK) Q2 2026 Earnings call February 17, 2026 04:15 PM ET Company ParticipantsJeff Stanlis - VP of CommunicationsJohn Merrill - CFORandy Fields - Chairman and CEOConference Call ParticipantsThomas Forte - Managing Director and Senior Consumer Internet AnalystOperatorGreetings, and welcome to the ReposiTrak Fiscal Second Quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone ...

Financial Data and Key Metrics Changes - For the second fiscal quarter of 2026, revenue increased by 7% from $5.5 million to $5.9 million [8] - Year-to-date total revenue increased by 8% from $10.9 million to $11.8 million [11] - GAAP net income for the second fiscal quarter was $1.7 million, up 9% from $1.6 million last year [9] - Earnings per share for the quarter was $0.09, reflecting a 13% year-over-year growth [10] - Total cash increased to $28.7 million from $28.6 million at the end of the previous quarter, with zero bank debt [10] Business Line Data and Key Metrics Changes - The company has converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue [4] - Income from operations increased by 34% to $1.8 million compared to $1.4 million [9] - The company has experienced growth across all lines of business, with cross-selling initiatives delivering continued momentum [12] Market Data and Key Metrics Changes - Traceability revenue is estimated to be between 8% and 10% of total revenue, indicating growth in this segment [32] - The company is positioned to benefit from increasing consumer awareness regarding food safety, driven by trends like MAHA and organic food movements [38] Company Strategy and Development Direction - The long-term strategy focuses on converting revenue streams to SaaS, paying down debt, and increasing contribution margins [4] - The company is investing in product development, including new solutions for tracking accuracy and operational cost reduction [6] - The filing of two patents for Touchless Traceability aims to create a competitive moat around the business [7][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of achieving consistent accuracy in supplier data, with error rates between 50% and 70% [18] - The company anticipates increased demand for traceability solutions as the FDA deadline approaches, which is expected to accelerate onboarding and interest in their offerings [26][49] - Management remains confident in the company's ability to provide unique solutions that address data quality issues in traceability [22] Other Important Information - The company has repurchased approximately 80,000 common shares for $1.1 million during the second quarter [13] - A quarterly dividend of $0.02 per share was declared, marking the third 10% increase since the dividend was established [16] Q&A Session Summary Question: What is the current percentage of revenue from traceability? - Management indicated that traceability revenue is between 8% and 10% of total revenue [32] Question: Can AI improve the accuracy of traceability data? - Management confirmed that their AI tools can detect and correct errors in traceability data, enhancing accuracy [34][35] Question: What is the impact of MAHA on the business? - Management noted that increased consumer awareness of food safety due to MAHA positively impacts their business [38] Question: Can the company provide traceability on a by-ingredient basis? - Management confirmed that their system can track products and ingredients, allowing for detailed traceability [40] Question: Does food inflation impact the business? - Management acknowledged that food inflation indirectly affects their business, particularly if supermarkets face margin squeezes [42] Question: How is investment spending reflected in the results? - Management explained that investment spending is more targeted, with less in marketing and more in development, affecting overall expenses [44][45] Question: What are the current thoughts on strategic M&A? - Management stated that while they are open to opportunities, their current focus is on existing projects and preparing for upcoming demand in traceability [47][50]

Financial Data and Key Metrics Changes - The company converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue since 2020 [4] - Net margin grew from 8% to over 30% during the same period [5] - GAAP net income for Q2 2026 was $1.7 million, up 9% from $1.6 million last year [9] - Fiscal 2026 year-to-date total revenue increased 8% from $10.9 million to $11.8 million [11] - Total cash increased to $28.7 million from $28.6 million at June 30, with zero bank debt [10] Business Line Data and Key Metrics Changes - The company is experiencing growth in all lines of business, with cross-selling initiatives delivering continued momentum [12] - Traditional sales are growing, and the focus on customer care and flawless execution remains paramount [12] Market Data and Key Metrics Changes - The ReposiTrak Traceability Network (RTN) is the industry leader, with a growing queue to join the network [16] - The company is addressing the challenge of data accuracy in traceability, with error rates from suppliers ranging between 50% and 70% [17] Company Strategy and Development Direction - The company aims to drive cash and return capital to shareholders while investing in product development and innovation [5][6] - Recent investments include filing for two patents related to Touchless Traceability, enhancing the company's competitive moat [6][23] - The focus on cross-selling and expanding the RTN is expected to generate significant traction [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of data accuracy in traceability and the need for complex process changes across the supply chain [17] - The looming FDA deadline for traceability is expected to accelerate interest in the company's solutions [25][47] - The company is preparing for increased demand for traceability solutions as the deadline approaches [48] Other Important Information - The company has repurchased approximately 80,000 common shares for $1.1 million during Q2 2026 [13] - The board declared a quarterly dividend of $0.02 per share, marking the third 10% increase since the dividend was established [15] Q&A Session Summary Question: What is the current revenue contribution from traceability? - Management indicated that traceability contributes between 8% and 10% of total revenue [31] Question: Can AI improve the accuracy of traceability data? - AI is utilized to detect and correct errors in traceability data, enhancing accuracy significantly [32][34] Question: What impact does MAHA have on the business? - MAHA increases public awareness of food safety, which indirectly benefits the company [37] Question: Can the company provide updates on traceability by ingredients? - The company is capable of tracking products and ingredients, allowing for detailed specifications [39] Question: Does food inflation impact the business? - Food inflation indirectly affects the business as supermarkets face margin squeezes [41] Question: How is investment spending reflected in the results? - Investment spending is more targeted, with less in marketing and more in development [42][43] Question: What are the current thoughts on strategic M&A? - The company is focused on existing initiatives and is not actively pursuing M&A at this time [45][48]

Q4 2025 Earnings Call FEBRUARY 17, 2026 1 Forward-looking statements Safe Harbor Statement Statements included in this presentation that are not a description of historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are generally accompanied by words or phrases such as "anticipate," "assume," "believe," "could," "estimate," "expect," "foresee," "goal," ...

Caesars Entertainment Investor Presentation February 17, 2026 Forward Looking Statements Certain information in this presentation constitutes forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts and by the use of words such as "will," "may," "expect," "project," "positioned," or the negative or other variations thereof or comparable terminology. In ...

NANO Nuclear Q1 2026 Financial Results & Business Update Call February 17 t h 2026 © 2026 NANO Nuclear Energy, Inc. All rights reserved. Cautionary Note Regarding Forward -Looking Statements This presentation and statements of NANO Nuclear's management in connection with this presentation contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-l ...

Fourth Quarter & Full-Year 2025 Financial Results February 2026 Cautionary Notes Cautionary Note Regarding Forward-Looking Information and Statements Except for statements of historical fact relating to us, certain statements contained in this presentation (including information incorporated by reference herein) constitute forward-looking information, future oriented financial information, or financial outlooks (collectively "forward-looking information") within the meaning of Section 27A of the Securities ...

Ingredion (NYSE:INGR) 2026 Conference February 17, 2026 04:00 PM ET Company ParticipantsJim Gray - EVP and CFOJim Zallie - President and CEOPatrick Kalotis - EVP of Global Textures and Healthful SolutionsRob Ritchie - EVP of Food and Industrial IngredientsModeratorWell, it's my pleasure to welcome Ingredion back to CAGNY, introduce President and CEO, Jim Zallie. Ingredion is a leader in global ingredient solutions, and Jim is building on more than 40 years in the food industry and 17 years with the company. ...